Professional Documents
Culture Documents
DAFTAR PUSTAKA
1. Creager M, Libby P. Peripheral Arterial Disease In: Mann DL, Zipes DP,
Libby P, Bonow RO, editors. Braunwald’s Heart Disease : A Textbook of
Cardiovascular Medicine. 10th ed. Philadelphia: Elsevier Saunders; 2015.
1312 p.
3. Rhee SY, Kim YS. Peripheral Arterial Disease in Patients with Type 2
Diabetes Mellitus. 2015;283–90.
8. Fowkes FGR, Low LP, Tuta S, Kozak J. Ankle-brachial index and extent of
atherothrombosis in 8891 patients with or at risk of vascular disease:
Results of the international AGATHA study. Eur Heart J.
2006;27(15):1861–7.
12. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL,
et al. ACC/AHA 2005 Practice Guidelines for the Management of Patients
With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and
Abdominal Aortic). Circulation. 2006;113(11):e463–5.
13. Norgren L, Hiatt WR, Dormandy J a., Nehler MR, Harris K a., Fowkes
FGR, et al. Inter-Society Consensus for the management of peripheral
arterial disease (TASC II). Int Angiol. 2007;26(2):82–157.
15. Marso SP, Hiatt WR. Peripheral arterial disease in patients with diabetes. J
Am Coll Cardiol. 2006;47(5):921–9.
16. The Japan Diabetes Society. Evidence-based Practice Guideline for the
Treatment for Diabetes in Japan 2013. Diabet Med. 2013;1–3.
17. Ilmiah Populer [Internet]. [cited 2016 Jan 26]. Available from:
http://www.pdpersi.co.id/content/popular_science.php?psid=30
18. Dinas Kesehatan Jateng. Daftar Tabel Profil Kesehatan Provinsi Jawa
Tengah. Semarang: Dinkes Jateng; 2008. 38 p.
19. Huh JH, Choi E, Lim JS, Lee MY, Chung CH, Shin JY. Serum cystatin C
levels are associated with asymptomatic peripheral arterial disease in type 2
diabetes mellitus patients without overt nephropathy. Diabetes Res Clin
Pract. Elsevier Ireland Ltd; 2015;108(2):258–64.
21. Tomeleri CM, Ronque ER, Silva DR, Cardoso Junior CG, Fernandes R a,
Teixeira DC, et al. Prevalence of dyslipidemia in adolescents: comparison
between definitions. Rev Port Cardiol. Sociedade Portuguesa de
Cardiologia; 2015;34(2):103–9.
25. Rinandyta SA. Perbedaan Kadar LDL pada Penderita Diabetes Melitus
Tipe 2 dengan Hipertensi dan Tanpa Hipertensi di RSUD Dr. Moewardi.
Universitas Muhammadiyah Surakarta; 2012.
27. Longo DL, Kasper DL, Jameson JL, Fauci AS, Hauser SL, Loscalzo J,
editors. Harrison’s Principles of Internal Medicine. 18th ed. New York: Mc
Graw Hill; 2012. 2066 p.
29. Runge MS, Greganti MA. Netter’s Internal Medicine. 2nd ed. Philadelphia:
Saunders Elsevier; 2009. 213 p.
31. Lozano FS, González-Porras JR, March JR, Lobos JM, Carrasco E, Ros E.
Diabetes mellitus and intermittent claudication: a cross-sectional study of
920 claudicants. Diabetol Metab Syndr. 2014;6:21.
33. Bordeaux LM, Reich LM, Hirsch AT. The Epidemiology and Natural.
Springer J. 2003;(Ic):21–35.
34. Baker. Smoking and Peripheral Arterial Disease ( PAD ). ASH Research
Report Smoking and Peripheral Arterial Disease. 2014;
36. Olin JW, Sealove B a. Peripheral artery disease: current insight into the
disease and its diagnosis and management. Mayo Clin Proc.
2010;85(7):678–92.
83
38. Age AT. Peripheral Arterial Disease in the Legs. In: CdcGov. p. 4–5.
39. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL.
ACC/AHA 2005 practice guidelines for the Management of Patients with
Peripheral Arterial Disease (lower extremity, renal, mesenteric, and
abdominal aortic): a collaborative report from the American Association for
Vascular Surgery/Society for Vascular Sur. Circulation. 2006;113(11):463–
654.
40. Suyono S. Diabetes Melitus. In: Setiati S, editor. Buku Ajar Ilmu Penyakit
Dalam. 1st ed. Jakarta: InternaPublishing; 2014. p. 2315–418.
42. Hirsch a T, Hiatt WR. PAD awareness, risk, and treatment: new resources
for survival--the USA PARTNERS program. Vasc Med. 2001;6(3
Suppl):9–12.
45. Forstermann U, Sessa WC. Nitric oxide synthases: regulation and function.
European Heart Journal. 2012;33(7):829–37.
50. Adam JM. Dislipidemia. In: Setiati S, editor. Buku Ajar Ilmu Penyakit
Dalam. 1st ed. Jakarta: InternaPublishing; 2014. p. 2549–68.
52. Jamkhande PG, Chandak PG, Dhawale SC, Barde SR, Tidke PS, Sakhare
RS. Therapeutic approaches to drug targets in atherosclerosis. Saudi Pharm
J SPJ Off Publ Saudi Pharm Soc. King Saud University; 2014;22(3):179–
90.
54. Aboyans V, Criqui MH, Abraham P, Allison M a., Creager M a., Diehm C,
et al. Measurement and Interpretation of the Ankle-Brachial Index: A
Scientific Statement From the American Heart Association. Circulation.
2012;126(24):2890–909.
55. Mahameed A Al. Peripheral Arterial Disease. Cleve Clin J Med. 2009;
58. WOCN Wound Committee. Ankle Brachial Index. J Wound, Ostomy Cont
Nurs. 2012;39(April):S21–9.
60. Yogiantoro M. Hipertensi Esensial. Buku Ajar Ilmu Penyakit Dalam Jilid
1. IV. Jakarta: FKUI; 2006. 610-14 p.
61. F Brian Boudi M. Treatment of Low HDL levels and High Triglyceride
levels in Patients With Diabetes. Medscape. 2016;[cited 2016 Jun 17]
85
62. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial
disease in the United States: Results from the National Health and Nutrition
Examination Survey, 1999-2000. Circulation. 2004;110(6):738–43.
63. Pepine CJ, Handberg EM. The vascular biology of hypertension and
atherosclerosis and intervention with calcium antagonists and angiotensin-
converting enzyme inhibitors. Clin Cardiol. 2001;24(11 Suppl):V1–5.
86
(INFORMED CONSENT)
terpilih sebagai peserta penelitian ini. Apabila Bapak/Ibu setuju untuk menjadi
peserta penelitian maka ada beberapa hal yang akan Bapak/Ibu alami, yaitu:
- Pengambilan informasi nama, umur, jenis kelamin, status merokok, status
hipertensi dan keluhan yang dirasakan melalui wawancara
- Diukur tekanan darah pada kedua kaki dan kedua lengan pada saat istirahat
- Dan bila diperlukan, akan diukur tekanan darah pada kaki setelah berolah
raga naik-turun bangku selama 4-5 menit atau berjalan selama 6 menit atau
dorsofleksi plantarfleksi selama 6 menit.
Keuntungan bagi Bapak/Ibu yang bersangkutan ikut dalam penelitian ini
adalah mendapat fasilitas pendeteksian Penyakit Arteri Perifer (PAP) serta
mengetahui derajat PAP yang diderita apabila terdeteksi. Dengan dilakukanya
pendeteksian ini, kita dapat mengetahui apakah terdapat sumbatan pembuluh
darah pada lengan atau kaki Bapak/Ibu. Bapak/Ibu juga akan diberi pemahaman
mengenai PAP. Saya menjamin bahwa penelitian ini tidak akan menimbulkan
efek yang merugikan pada Bapak/Ibu. Dalam penelitian ini tidak ada intervensi
dalam bentuk apapun terhadap Bapak/ Ibu. Setiap data pemeriksaan dan penelitian
dijamin kerahasiaannya dengan tidak mencantumkan identitas subyek. Sebagai
peserta penelitian keikutsertaan ini bersifat sukarela dan tidak dikenakan biaya
penelitian.
Tegal, …………………….2016
Saksi
Nama Terang : Nama Terang :
Alamat : Alamat :
88
Lampiran 2
Lampiran 3
Kelengkapan Data
Status Merokok :
Lamanya DM :
Lamanya Dislipidemia
Minum obat hipertensi teratur atau tidak :
Minum obat diabetes teratur atau tidak :
Minum obat dislipidemia teratur atau tidak :
91
Frequencies
Frequency Table
Status Dislipidemia
Frequency Percent Valid Percent Cumulative
Percent
ya 21 70,0 70,0 70,0
Valid tidak 9 30,0 30,0 100,0
Total 30 100,0 100,0
Jenis kelamin
Frequency Percent Valid Percent Cumulative
Percent
Laki-laki 17 56,7 56,7 56,7
Valid Perempuan 13 43,3 43,3 100,0
Total 30 100,0 100,0
Usia
Valid 30
N
Missing 0
Mean 59,17
Median 58,50
Std. Deviation 7,250
Minimum 46
Maximum 71
Usia
Frequency Percent Valid Percent Cumulative
Percent
46 2 6,7 6,7 6,7
50 2 6,7 6,7 13,3
51 1 3,3 3,3 16,7
52 1 3,3 3,3 20,0
53 2 6,7 6,7 26,7
Valid 54 2 6,7 6,7 33,3
55 2 6,7 6,7 40,0
57 1 3,3 3,3 43,3
58 2 6,7 6,7 50,0
59 1 3,3 3,3 53,3
62 1 3,3 3,3 56,7
97
Status merokok
Frequency Percent Valid Percent Cumulative
Percent
Ya 6 20,0 20,0 20,0
pasif 5 16,7 16,7 36,7
Valid mantan 3 10,0 10,0 46,7
tidak 16 53,3 53,3 100,0
Total 30 100,0 100,0
Hipertensi
Frequency Percent Valid Percent Cumulative
Percent
Ya 13 43,3 43,3 43,3
Valid Tidak 17 56,7 56,7 100,0
Total 30 100,0 100,0
Crosstabs
Case Processing Summary
Cases
Valid Missing Total
N Percent N Percent N Percent
Status Dislipidemia * Status 30 100,0% 0 0,0% 30 100,0%
PAP
98
Chi-Square Tests
Value df Asymp. Sig. (2- Exact Sig. (2- Exact Sig. (1-
sided) sided) sided)
a
Pearson Chi-Square 8,571 1 ,003
b 6,356 1 ,012
Continuity Correction
N of Valid Cases 30
a. 1 cells (25,0%) have expected count less than 5. The minimum expected count is 3,60.
b. Computed only for a 2x2 table
Risk Estimate
Value 95% Confidence Interval
Lower Upper
For cohort Status PAP = ,429 ,262 ,702
Tidak
N of Valid Cases 30
99
T-Test
Group Statistics
Status PAP N Mean Std. Deviation Std. Error Mean
Ya 12 212,00 45,798 13,221
Kolesterol total
Tidak 9 164,33 34,077 11,359
T-Test
Group Statistics
Status PAP N Mean Std. Deviation Std. Error Mean
Ya 12 136,83 31,007 8,951
LDL
Tidak 9 104,44 30,566 10,189
T-Test
Group Statistics
Status PAP N Mean Std. Deviation Std. Error Mean
Ya 12 25,58 9,549 2,756
HDL
Tidak 9 33,67 5,074 1,691
NPar Tests
Mann-Whitney Test
Ranks
Status PAP N Mean Rank Sum of Ranks
Ya 12 13,42 161,00
Trigliserida Tidak 9 7,78 70,00
Total 21
a
Test Statistics
Trigliserida
Mann-Whitney U 25,000
Wilcoxon W 70,000
Z -2,061
Asymp. Sig. (2-tailed) ,039
b
Exact Sig. [2*(1-tailed Sig.)] ,041
a. Grouping Variable: Status PAP
b. Not corrected for ties.
101
Crosstabs
Case Processing Summary
Cases
a. 6 cells (75,0%) have expected count less than 5. The minimum expected count is
,43.
102
Frequencies
jenis komponen
Frequency Percent Valid Percent Cumulative
Percent
HDL 4 19,0 19,0 19,0
TG 2 9,5 9,5 28,6
TC HDL 1 4,8 4,8 33,3
HDL TG 10 47,6 47,6 81,0
Valid
LDL HDL 1 4,8 4,8 85,7
TC LDL HDL 2 9,5 9,5 95,2
TC LDL HDL TG 1 4,8 4,8 100,0
Total 21 100,0 100,0
NPar Tests
Descriptive Statistics
Mann-Whitney Test
Ranks
Status PAP N Mean Rank Sum of Ranks
Ya 12 14,38 172,50
jenis komponen Tidak 9 6,50 58,50
Total 21
a
Test Statistics
jenis komponen
Mann-Whitney U 13,500
Wilcoxon W 58,500
Z -3,059
Asymp. Sig. (2-tailed) ,002
b
Exact Sig. [2*(1-tailed Sig.)] ,002
a. Grouping Variable: Status PAP
b. Not corrected for ties.
Crosstabs
Case Processing Summary
Cases
Valid Missing Total
N Percent N Percent N Percent
Jenis kelamin * Status PAP 30 100,0% 0 0,0% 30 100,0%
Chi-Square Tests
Value df Asymp. Sig. (2- Exact Sig. (2- Exact Sig. (1-
sided) sided) sided)
a
Pearson Chi-Square ,362 1 ,547
b ,051 1 ,821
Continuity Correction
Likelihood Ratio ,361 1 ,548
N of Valid Cases 30
a. 0 cells (0,0%) have expected count less than 5. The minimum expected count is 5,20.
b. Computed only for a 2x2 table
Risk Estimate
Value 95% Confidence Interval
Lower Upper
Odds Ratio for Jenis kelamin ,636 ,145 2,784
(Laki-laki / Perempuan)
For cohort Status PAP = Ya ,765 ,320 1,828
For cohort Status PAP = 1,202 ,651 2,220
Tidak
N of Valid Cases 30
T-Test
Group Statistics
Status PAP N Mean Std. Deviation Std. Error Mean
Ya 12 61,08 6,302 1,819
Usia
Tidak 18 57,89 7,722 1,820
Crosstabs
Case Processing Summary
Cases
Valid Missing Total
N Percent N Percent N Percent
Status merokok * Status 30 100,0% 0 0,0% 30 100,0%
PAP
Chi-Square Tests
Value df Asymp. Sig. (2-
sided)
a
Pearson Chi-Square 4,167 3 ,244
Likelihood Ratio 4,199 3 ,241
Linear-by-Linear Association 3,902 1 ,048
N of Valid Cases 30
106
Risk Estimate
Value
a
Odds Ratio for Status
merokok (Ya / pasif)
Crosstabs
Case Processing Summary
Cases
Valid Missing Total
N Percent N Percent N Percent
Hipertensi * Status PAP 30 100,0% 0 0,0% 30 100,0%
Chi-Square Tests
Value df Asymp. Sig. (2- Exact Sig. (2- Exact Sig. (1-
sided) sided) sided)
a
Pearson Chi-Square 8,167 1 ,004
b 6,160 1 ,013
Continuity Correction
Likelihood Ratio 8,488 1 ,004
N of Valid Cases 30
a. 0 cells (0,0%) have expected count less than 5. The minimum expected count is 5,20.
b. Computed only for a 2x2 table
Risk Estimate
Value 95% Confidence Interval
Lower Upper
Odds Ratio for Hipertensi 10,500 1,889 58,359
(Ya / Tidak)
For cohort Status PAP = Ya 3,923 1,320 11,656
For cohort Status PAP = ,374 ,161 ,869
Tidak
N of Valid Cases 30
Crosstabs
Case Processing Summary
Cases
Valid Missing Total
N Percent N Percent N Percent
Penyakit atherosclerosis lain 30 100,0% 0 0,0% 30 100,0%
* Status PAP
Chi-Square Tests
Value df Asymp. Sig. (2- Exact Sig. (2- Exact Sig. (1-
sided) sided) sided)
a
Pearson Chi-Square 1,118 1 ,290
b ,380 1 ,537
Continuity Correction
N of Valid Cases 30
a. 2 cells (50,0%) have expected count less than 5. The minimum expected count is 2,80.
b. Computed only for a 2x2 table
Risk Estimate
Value 95% Confidence Interval
Lower Upper
Odds Ratio for Penyakit 2,500 ,445 14,037
atherosclerosis lain (Ya /
Tidak)
For cohort Status PAP = Ya 1,643 ,701 3,849
For cohort Status PAP = ,657 ,266 1,626
Tidak
N of Valid Cases 30
Crosstabs
Minum obat * Status PAP Crosstabulation
Status PAP Total
Ya Tidak
Count 6 16 22
Expected Count 8,8 13,2 22,0
Teratur
Minum obat % within Status PAP 50,0% 88,9% 73,3%
% of Total 20,0% 53,3% 73,3%
Tidak teratur Count 6 2 8
109
Chi-Square Tests
Value df Asymp. Sig. (2- Exact Sig. (2- Exact Sig. (1-
sided) sided) sided)
a
Pearson Chi-Square 5,568 1 ,018
b 3,757 1 ,053
Continuity Correction
Likelihood Ratio 5,601 1 ,018
N of Valid Cases 30
a. 2 cells (50,0%) have expected count less than 5. The minimum expected count is 3,20.
b. Computed only for a 2x2 table
Risk Estimate
Value 95% Confidence Interval
Lower Upper
Odds Ratio for Minum obat ,125 ,020 ,799
(Teratur / Tidak teratur)
For cohort Status PAP = Ya ,364 ,165 ,802
For cohort Status PAP = 2,909 ,853 9,925
Tidak
N of Valid Cases 30
Crosstabs
Case Processing Summary
Cases
Valid Missing Total
N Percent N Percent N Percent
Obat dislipidemia * Status 30 100,0% 0 0,0% 30 100,0%
PAP
110
Chi-Square Tests
Value df Asymp. Sig. (2-
sided)
a
Pearson Chi-Square 6,632 2 ,036
Likelihood Ratio 9,068 2 ,011
Linear-by-Linear Association 5,695 1 ,017
N of Valid Cases 30
Risk Estimate
Value
a
Odds Ratio for Obat
dislipidemia (ya / tidak)
Crosstabs
Case Processing Summary
Cases
Valid Missing Total
N Percent N Percent N Percent
obat hipertensi * Status PAP 30 100,0% 0 0,0% 30 100,0%
Chi-Square Tests
Value df Asymp. Sig. (2-
sided)
a
Pearson Chi-Square 8,198 2 ,017
Likelihood Ratio 8,523 2 ,014
Linear-by-Linear Association 7,016 1 ,008
N of Valid Cases 30
Risk Estimate
Value
a
Odds Ratio for obat
hipertensi (teratur / tidak
teratur)
Logistic Regression
Case Processing Summary
a
Unweighted Cases N Percent
Included in Analysis 30 100,0
Selected Cases Missing Cases 0 ,0
Total 30 100,0
Unselected Cases 0 ,0
Total 30 100,0
a. If weight is in effect, see classification table for the total number of cases.
Model Summary
Step -2 Log likelihood Cox & Snell R Nagelkerke R
Square Square
a
1 29,589 ,302 ,408
a
2 31,892 ,246 ,333
a. Estimation terminated at iteration number 4 because parameter
estimates changed by less than ,001.
a
Classification Table
Observed Predicted
Status PAP Percentage
Ya Tidak Correct
Ya 9 3 75,0
Status PAP
Step 1 Tidak 4 14 77,8
Overall Percentage 76,7
Ya 9 3 75,0
Status PAP
Step 2 Tidak 4 14 77,8
Overall Percentage 76,7
Lower Upper
Hipertensi(1) -2,017 ,919 4,820 1 ,028 ,133 ,022 ,805
a
Step 1 obat_dm(1) 1,552 1,048 2,190 1 ,139 4,719 ,604 36,836
Constant ,250 1,055 ,056 1 ,813 1,284
a
Variables obat_dm(1) 2,360 1 ,124
Step 2
Overall Statistics 2,360 1 ,124
a. Variable(s) removed on step 2: obat_dm.